Natera competitors, on the record
The companies Natera names as competitors in its annual reports, 2023 to 2025, and the companies that name Natera, each with the sentence and the filing.
Who Natera names
| Company | Named in |
|---|---|
| BGI | 2025 |
| BillionToOne Inc. | 2025 |
| CareDx, Inc. | 2025 |
| Caris Life Sciences, Inc. | 2025 |
| Exact Sciences Corp. | 2025 |
| Fulgent Genetics | 2025 |
| Guardant Health, Inc. | 2025 |
| Illumina | 2025 |
| Laboratory Corporation of America Holdings | 2025 |
| Myriad Genetics, Inc. | 2025 |
| Personalis, Inc. | 2025 |
| Quest Diagnostics Incorporated | 2025 |
| Revvity Inc. | 2025 |
| Tempus Labs, Inc. | 2025 |
| Verinata Health Inc. | 2025 |
In its own words
BGI, BillionToOne Inc., Fulgent Genetics, Illumina, Laboratory Corporation of America Holdings, Myriad Genetics, Inc., Quest Diagnostics Incorporated, Revvity Inc.
Word for word“Our competitors in the NIPT space include BGI; BillionToOne Inc.; Fulgent Genetics; Illumina, through its subsidiary Verinata; Laboratory Corporation of America Holdings, or Labcorp; Myriad Genetics, Inc.; Quest Diagnostics Incorporated, or Quest; and Revvity Inc.” 10-K for 2025
CareDx, Inc.
Word for word“In organ health, our primary competitor is CareDx, Inc.” 10-K for 2025
Caris Life Sciences, Inc., Exact Sciences Corp., Guardant Health, Inc., Personalis, Inc., Tempus Labs, Inc.
Word for word“In the field of oncology, we compete with various companies that offer or seek to offer competing solutions, such as BillionToOne Inc.; Caris Life Sciences, Inc.; Exact Sciences Corp.; Guardant Health, Inc.; Personalis, Inc.; Quest; and Tempus Labs, Inc.” 10-K for 2025
Verinata Health Inc.
Word for word“In addition, Illumina competes with us in the NIPT market through its subsidiary, Verinata.” 10-K for 2025
Who names Natera
Companies whose own annual reports name Natera as a competitor.
Word for word“We face competition from a variety of sources, including Ambry Genetics (owned by Tempus AI); Myriad Genetics, Inc.; Natera; Color Health, Inc.; GeneDx; Illumina; Variantyx; 3billion; a few large, established general testing companies such as Laboratory Corporation of America Holdings (LabCorp) and Quest Diagnostics Incorporated; and clinical laboratories in an academic or healthcare provider setting that perform clinical genetic testing on behalf of their affiliated institutions.” 10-K for 2025
Word for word“Our primary competitors for our currently marketed precision oncology tests include Foundation Medicine, Inc., which was acquired by Roche Holdings, Inc., Caris Life Sciences, Guardant Health, Inc., Natera, Neogenomics, ResolutionBio, which was acquired by Agilent, and others.” 10-K for 2025
Read from Natera’s annual reports (10-K for 2025, 10-K for 2024, 10-K for 2023) and the financial data it files with the SEC, as of 2026-02-27. Every quotation is word for word from the filing linked beside it; how these pages are built and checked. The full record is in its company data sheet.